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Summary It is important that the introduction of breast screening is closely monitored. The anticipated
effect on breast cancer mortality will take 10 years or more fully to emerge, and will only occur if a
succession of more short-term end points are met. Data from the Swedish two-county randomised trial
provide targets that should be achieved, following a logical progression of compliance with the initial
invitation, prevalence and stage distribution at the prevalence screen, the rate of interval cancers after the
initial screen, the pick-up rate and stage distribution at later screening tests, the rate of interval cancers after
later tests, the absolute rate of advanced cancer and finally the breast cancer mortality rate. For evaluation
purposes, historical data on stage at diagnosis is desirable; it is suggested that tumour size is probably the
most relevant variable available in most cases.
Screening for breast cancer is being introduced in Britain on
the recommendation of the Forrest Report. Experience from
the cervical cancer screening programme has demonstrated
that the performance of a national programme may fall
below expectation based on experience from specialist UK
centres, or from other countries. It is therefore important to
monitor the performance of the national breast cancer
screening programme from its inception, to determine how
closely the benefits it achieves approach the benefits seen in
the randomised trials and population demonstration projects,
the results of which formed the basis for the Forrest
Report's recommendation.
The most relevant of the trials which have so far reported
results is the Swedish two-county study (Tabar et al., 1985),
for a number of reasons. It used mammography as the sole
screening modality, and for the age group of relevance,
women aged 50-64 years, the average inter-screening interval
(33 months) was similar to the 3-year interval to be adopted
in Britain. It also screened over 30,000 women in this age
group, compared to the 15,000 or fewer screened in Florence
(Palli et al., 1986), Nijmegen (Verbeek et al., 1984) or
Utrecht (de Waard et al., 1984). It is thus of interest to
examine the different evaluation measures that emerged from
the Swedish study, to identify the information on which
these measures are based and at what stage in the trial this
information became available. The emphasis in this paper is
on the fundamental effect measure, breast cancer mortality.
Measures relating to other important aspects of the screening
programme, for example costs, quality of care or the value
of different diagnostic procedures, are not considered.
Results of the Swedish two-county study
The three main criteria one can use in evaluating the effect
of the screening programme are: (1) changes in mortality; (2)
changes in the absolute rate of advanced disease; (3)
parameters of the screening process, comprising both the
screening test and the further diagnostic procedures applied
to women positive on the screening test - these parameters
include sensitivity, specificity, the distribution of lead time
(the length of time diagnosis is advanced by screening) and
sojourn time (the length of time preclinical lesions are
detectable by screening), and the predictive value for
malignancy.
Mortality of course is the basic evaluation measure. In the
Swedish study, however, no difference between the study and
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control group was seen until the fourth year. It was not until
the end of the seventh year that the gap had widened
sufficiently, and adequate numbers accrued, for one to be
satisfied that breast cancer mortality had been reduced.
Similarly, in Utrecht (Collette et al., 1984) and Nijmegen
(Verbeek et al., 1984), at least 7 years elapsed after the start
of screening before the effect on mortality was able to be
assessed. Although similar evaluation will be necessary in
this country, 7 years or more is a long time to wait before
one can determine whether the programme is effective.
Earlier measures are required.
The effect on mortality is the result of earlier diagnosis,
which is seen in the reduction in 4he rate of advanced
disease. This reduction in advanced disease, if it occurs, will
be detectable earlier than the reduction in mortality. Figure
1 gives the corresponding results for advanced disease
(Figure la) and breast cancer deaths (Figure lb) for the
group aged 50-59 years at study entry from the two-county
study. One can see that the gap between the two curves
begins to appear some 2 years earlier for the advanced
cancers than for the deaths.
The reduction in advanced disease results from earlier
diagnosis and so depends on the lead time distribution of
cases diagnosed by screening. This distribution expresses
quantitatively the length of time by which diagnosis has been
advanced. It is reflected in the incidence of interval cancers
among screened women in the years following a negative
screening test (Day & Walter, 1984). To be informative, the
incidence of interval cancers needs to be expressed as a
proportion of the incidence that would have been expected
in the absence of screening, as shown in Figure 2 from the
two-county study (Tabar et al., 1987a).
The difference between the incidence rate of interval
cancers and the rate expected in the absence of screening
reflects the number of cancers with a diagnosis that was
advanced to the previous screening test. An initial indication
of the incidence rate of interval cancers (i.e. as in Figure 2)
is therefore given by the prevalence rate of cancers detected
at the first screen. As with interval cancers, this rate is more
informatively expressed if divided by the incidence rate
expected in the absence of screening in women presenting for
screening. Results from the two-county study are given in
Table I. Since, however, some of these cancers may not have
been destined to surface clinically until much later, if at all,
and may have low malignant potential, this prevalence is not
an adequate surrogate measure of the rate of interval
cancers. Both need to be considered.
The more favourable stage distribution obtained in the
group invited for screening arises because the cancers whose
diagnosis was brought forward in time by early detection,
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Figure 1 (a) Cumulative rates per 104 women of advanced cancers and (b) cumulative mortality rates per 105 women in the
Swedish 2-county study.
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Figure 2 Incidence of breast cancer among screeped women.
are diagnosed at an earlier stage. Table II gives the
proportion of stage II or worse of cancers detected at the
first screen, of interval cancers, of cancers detected at the
second or later screen, and of cancers seen in the control
group (Tabar et al., 1987). The similarity of the interval and
the control group cancers is striking. Table II also gives the
size distribution of screen-detected cancers and of cancers
diagnosed in the control group. That the screen-detected
Table I Swedish two-county study: prevalence per 1,000 women of
breast cancer detected at the initial screening test
Underlying incidence
Prevalence rate per 1,000 Prevalencel
Age group per 1,000 person years incidence
50-59 4.63 1.50 3.09
60-69 9.08 1.98 4.59
Table II Stage distribution by means of detection: age group 50-69
Swedish two-county study
Initial Second or Interval Control
Age group screen later screen cancers group
Proportion of stage II or worse cancers
50-59 33.3 25.0 55.3 58.7
60-69 34.3 16.9 58.5 58.4
Tumour size (mm)
1-9 10-14 15-19 >20 Total
Distribution (%) of tumour size, invasive cancers only
Screen-detected 23 29 22 26 414
Control group 7 15 18 59 461
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cancers should have a more favourable stage distribution
and be of smaller size is a prerequisite for the subsequent
deficit of advanced cancers in the group allocated to
screening, necessary but not sufficient.
Finally, the effect of the programme on the subsequent
rates of advanced disease and mortality will depend directly
on the proportion of the target population who present for
screening. Compliance rate is clearly an important initial
measure - necessary but not sufficient - of programme
effectiveness. In the Swedish two-county study, compliance
in the age group 50-64 was of the order of 90%.
Implications for the information requirements of a regional
and national evaluation system
The foregoing description of the process whereby screening
leads to a reduction in breast cancer mortality pinpoints the
information required to determine whether the programme is
on course. Table III summarises a minimum set of measures
that an information system should monitor to evaluate the
effectiveness of the programme in reducing severity of and
mortality from the disease. The first three measures (com-
pliance, screening characteristics and rate of advanced
cancers) are not in themselves sufficient to demonstrate a
reduction in mortality. A favourable value for each of these
measures is necessary, however, if an acceptable effect on
breast cancer mortality is to be achieved. Poor performance
indicates where remedial action is required. The information
required to monitor these performance measures is described
below.
Compliance rate
It is important that the real compliance rate is measured, i.e.
the proportion who present for screening among the women
invited who are both alive and resident in the catchment
population. One needs to ascertain the accuracy of the
population lists that are used.
Characteristics of the screening procedures
Prevalence rate at the first screen This measure should be
by 5-year age group, since rates increase rapidly with age.
One has the approximate relationship:
Prevalence rate at first screen sensitivity x average sojourn
Expected incidence rate time
This expression indicates that to be informative in terms of
the underlying screening parameters, and so for comparison
with other programmes, the prevalence rate needs to be
expressed as a multiple of the expected annual incidence rate
in screened women (i.e. the rate one would have seen in the
Table III Measure of performance, satisfactory values of which are
necessary to obtain an acceptable reduction in breast cancer
mortality
Measure Rationale
Compliance rate Mortality reduction in target
population directly related to %
compliance
Screening characteristics, in To achieve results comparable to
particular: the Swedish study, the screening test
sensitivity as performed should be comparable
lead time distribution in its characteristics
sojourn time distribution
stage distribution among
screen-detected cancers
compared to that among
a comparable group of
clinically diagnosed
cancers
Rate of advanced cancers Earlier surrogate of mortality rates
Breast cancer mortality
absence of screening). This incidence rate is not directly
observable, but it can be derived from the expected rate in
the total population and the rate in non-attenders. The rate
in non-attenders is directly observable provided that the
population is covered by cancer registration of high quality,
and that the non-attenders are well identified. For the latter
one needs to know, among the women who were invited but
did not attend, the proportion alive and living in the
catchment area (as for the assessment of compliance).
Estimates of the rate in the total population, which is not
directly observable, can be obtained either from rates in
comparable, neighbouring unscreened populations or from
historical incidence data. Both require cancer registration
and the latter requires the existence of good quality cancer
registration in previous years. The expected rate among the
attenders is then obtained from the identity:
Incidence rate in total population
=Pxincidence rate in attenders
+(1-P) x incidence rate in refusers
where P is the real compliance rate (expressed as a
proportion).
Incidence ofinterval cancers Registration of interval cancers
requires coverage of the population by good cancer regist-
ration. As noted before, it is important to express the rate of
interval cancers as a proportion of the expected rate in the
screened group, which requires the expected incidence rate in
the total population and the incidence rate among
non-attenders.
Comparison of the interval cancer rates and the initial
prevalence rates with those seen in the two-county study will
indicate whether the following parameters of the screening
process (i.e. screening test and associated diagnostic pro-
cedures) are comparable to those seen in an effective pro-
gramme: (1) sensitivity; (2) distribution of sojourn time and
lead time; (3) 'overdiagnosis' of breast cancer - this appeared
to be absent from the two-county study (Day et al., 1988),
but has been suspected elsewhere. It would be surprising if
comparable values for sensitivity and the sojourn time
distribution did not lead to comparable effects on mortality
and advanced disease.
Stage distribution of screen detected cancers As can be seen
from Table II, the stage distribution of cancers detected at
the first screen may differ from that seen at later screens.
The definition of stage needs to take account of the infor-
mation likely to be available in the majority of cases.
Tumour size may be an acceptable substitute for stage, as
discussed in the next section. The stage (or tumour size)
distribution of screen detected cancers needs to be compared
to the stage distribution one would have expected in the
absence of screening among women who presented for
screening. This latter distribution can be obtained from the
stage distribution of cancers among non-attenders and that
of cancers in the total population before the start of the
programme.
Absolute rates of advanced cancers
There are two problems in the use for evaluation of the rate
of advanced cancers. First is the definition of an advanced
cancer. Second is the choice of comparison groups.
Definition ofan advanced cancer In the Swedish two-county
study, 'advanced' meant stage II or worse with histological
examination of the nodes. Thus a stage I cancer had to be
less than 20mm diameter, and no involvement of the nodes,
with an adequate number examined. Although screen-
detected cancers may be sufficiently investigated to give
acceptable stage information, many cancers diagnosed clini-
cally will not be. Any comparison group will clearly be
formed of the latter, and cancer registry information will beBREAST CANCER SCREENING PROGRAMMES 957
Table IV Monitoring measures and the associated information requirements
Measure Qualifying comments Additional information required Type of evaluation provided
Compliance rate Validation of population list Identification of real non-compliance Indicates potential for effectiveness
of the overall programme
Prevalence rate at Expressed as multiple of expected Incidence rates in non-compliers and)
initial screening test incidence rate in screened women in a comparable unscreened group, Provide estimates of sensitivity, lead e.g. historical rates tImesojoum etimaes and predictivlea Rate of interval Expressed as a proportion of Accurate identification of interval time, sojourn time and predictive
cancers expected incidence rate in screened cancers, and calculation of J value
women, and by time since the last additional incidence rates as above
screening test
Stage (or size) Compared to expected stage Stage (or size) distribution in non- Indicates potential for reduction in
distribution of screen- distribution in the absence of compliers and in total population absolute rate of advanced cancer
detected cancers: screening before screening started
(1) at initial screen;
(2) at subsequent
screen
Rate of advanced Need for a definition of 'advanced' Stage (or tumour size) information Earlier surrogate of mortality
cancers which can be used for the great needed historically, and on cancers
majority of cases given the among non-compliers
information available. Probably
based on tumour size
Breast cancer death Breast cancer deaths linked to date Final evaluation
rate of diagnosis
needed for staging. Examination of retrospective data in the
East Anglian cancer registry (de Bono & Kingsley-Pillers,
1978), indicates that the most frequent information missing
for staging purposes is status of the nodes, which makes the
important distinction between stage I and stage II imposs-
ible. Tumour size is frequently present, and when absent
there are often clear indications that the tumour is inoper-
able and advanced. That is, for cancers small enough to be
stage I, information on tumour size is only rarely absent.
Use of tumour size as a surrogate for stage can be argued
for since: (1) tumour size is of strong prognostic value in its
own right; (2) the proportion with positive nodes is strongly
related to tumour size and this relationship is the same in
screen detected as in clinically detected cases (Tabar et al.,
1987b). This last point suggests that screen detected small
cancers are similar in behaviour to clinically detected small
cancers. If tumour size is used, it can either be dichotomised
at say 15 or 20mm, to give 'early' and 'advanced' cancers,
or subdivided more finely. The first approach is simpler and
may prove equally informative.
Table V Suggested levels beyond which corrective action is strongly
indicated
Measure Acceptable level
Compliance rate No less than 60%
Prevalance rate at first No less than three times the underlying
screening test incidence rate
Rate of interval cancers No more than 25% of expected
incidence in first 2 years after a
negative test, and no more than 60%
of expected incidence in the third year
Stage distribution of
screen-detected cancers
At first test No more than 40% stage II or more
advanced
At subsequent tests No more than 30% stage II or more
advanced
Reduction in rate of No less than 30% in target population,
advanced cancers seven years after first invitation sent
Reduction in breast No less than 25% in target population
cancer mortality rates free from breast cancer when first
invitation sent, 10 years after
programme starts
Choice ofcomparison groups Three approaches are possible:
(1) The target population can be compared with historical
data covering the same age group and geographic area. A
figure comparable to Figure la would result, where the
'control' group data are replaced by expected numbers for
the target population based on historical cancer registry
data. There is the possibility of confounding with secular
change in stage of presentation, but the historical data can
be examined for such changes. One can also examine current
data in age groups outside those targeted for screening, for
any indication of secular trends. (2) The target population
can be compared with a geographically neighbouring popu-
lation. This comparison can only be made while the
programme is being introduced, and is thus of limited
usefulness. It would require incidence rates by small geo-
graphic area. (3) A comparison of screened with unscreened
women using either a case control approach or data from
the entire cohort. This comparison evidently runs a serious
risk of bias. One would need to compare rates in the
unscreened women with historical data, to assess selection
biases affecting both underlying incidence rates and stage at
presentation. In the Utrecht case-control study of breast
cancer deaths, these comparisons were made and bias was
thought to be small. In the HIP study and the two-county
study, selection bias was strong but acted in different
directions. In New York, unscreened women were at low risk
for breast cancer, in Sweden unscreened women presented
with particularly late stage cancers. This approach avoids
problems due to secular trends, so that combining it with the
comparison with historical data strengthens both. Such a
combined approach has recently been adopted in a further
analysis of the Utrecht study.
Breast cancer mortality
Evaluation of the effect on mortality can take the three
approaches described in the previous section, but concentrat-
ing on breast cancer deaths occurring among breast cancer
cases diagnosed after the start of the screening programme.
For this purpose, date of diagnosis will be required for all
breast cancer deaths in the region for a number of years
before the trial starts. Mortality comparison can then be
constructed equivalent to Figure lb using historical infor-
mation for the controls.958 N.E. DAY et al.
Conclusions
The scheme for an information system described above is
shown in Table IV with the time sequence in Figure 3. It
follows the process of screening from the start, the identifica-
tion of the target population, to the final evaluation mea-
sure, the effect on breast cancer mortality. The information
measures described plot the course that the programme has
to follow to achieve the results on breast cancer mortality
expected from the Swedish randomised trial. Table V pro-
poses minimum levels of performance for each of these
measures. The only aspect not considered is treatment; it is
clear that a reduction in mortality will result from the
achievement of earlier diagnosis only if the early lesions are
adequately treated.
Years since start of programme
0 1 2 3 4 5 6 7 8 9 10
First Screening Round
Second Screening Round
Third Screening Round
Compliance at 1st round. Compliance at 2nd round.
Prevalence and stage Prevalence and stage distribution
distribution at first at second round.
screening test.
Incidence rate of Incidence rate of
interval cancers interval cancers
after first round. after second round.
Evaluation in terms of Evaluation in terms
rate of advanced cancers. of mortality
Figure 3
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